NSP · Insperity, Inc · Stock research

Current Thesis

Insperity is a professional employer organization (PEO) — it leases HR, payroll, and benefits administration to small and mid-sized US employers, and its single most important number is average paid worksite employees (WSEs). That number is shrinking: 303,049 in Q1 2026, down ~1% YoY (call 2026-05-01). The equity has already round-tripped violently — from a 52-week low of $18.57 to ~$48.35 (2026-07-24), a ~160% recovery — powered by a margin-repair story plus the 2026-02-26 general-availability launch of Insperity HRScale with Workday. That is a genuine narrative leg, but it is a turnaround off a washed-out base, not an accelerating momentum tape. WSEs still contract, GAAP profit is depressed, and the Q2 print on 2026-07-29 is a hard binary. For a momentum book this is dormant: the big mean-reversion move is behind it and the next leg is gated by an earnings gamble.

Bullish and bearish views on Insperity, Inc

The model's bull view on Insperity, Inc (NSP), in brief: Margin recovery is real and ahead of schedule. The bear view: The core engine is contracting. Average paid WSEs fell ~1% YoY in Q1 2026 and printed at the low end of the forecast range. Full-year guidance of 303,000–307,000 implies a 1–2.3% decline. A PEO whose worksite headcount shrinks has no organic top-line engine; revenue growth (~2%… Both cases follow in full.

Bull Case

• Margin recovery is real and ahead of schedule. Q1 2026 adjusted EBITDA was $103M and adjusted EPS $1.31, beating the $1.24 consensus (reported 2026-05-01). Management said gross-profit-per-WSE recovery outpaced its own scheduled cadence, which is why full-year adjusted-EBITDA guidance ($170–230M) held despite a shrinking employee base.
• Workday HRScale is the growth optionality. The co-branded PEO-plus-Workday-HCM product hit general availability 2026-02-26. Early co-selling feedback cited clients willing to pay a 10–15% premium, and management has framed $500M+ of incremental revenue potential by 2028. If that converts, the WSE decline reverses and the multiple re-rates.
• Turnaround optics and a divided-but-improving Street. Recent single-firm targets sit at $52 (Truist, maintained Hold, raised PT 2026-07-22) and $54 (Roth, May 2026), both above spot. The name recovered off deep-value levels ($18.57 low) as the 2025 benefits-cost blowup annualized out of the comps.
• ~5% dividend ($0.60/quarter, $2.40 annualized) pays the wait — though this cuts both ways (see traps below).

Bear Case

• The core engine is contracting. Average paid WSEs fell ~1% YoY in Q1 2026 and printed at the low end of the forecast range. Full-year guidance of 303,000–307,000 implies a 1–2.3% decline. A PEO whose worksite headcount shrinks has no organic top-line engine; revenue growth (~2% YoY in Q1) is pricing, not volume.
• Reported earnings are hollow. GAAP net income fell ~35% YoY to $33M in Q1 2026, and trailing-twelve-month net income is negative (~-$25M), so there is no meaningful P/E. The forward P/E near ~22 already prices a recovery that WSE trends have not yet delivered.
• Guidance has been the wound, not the salve. The Q1 beat was overshadowed by soft guidance that sank the shares. The Q2 range (adjusted EPS $0.02–$0.50) is unusually wide — an admission of low forward visibility.
• Structural margin risk is health-cost inflation. The 2025 blowup came from benefits/medical-cost pass-through. This is a health-cost-carrying business, so an insurance-inflation reacceleration re-opens the same wound.
• Consensus is Hold, and some aggregators peg the blended 12-month target below spot even as individual banks sit at $52–54 — a split Street, not a conviction narrative.

Setup & Price Structure

• Spot ~$48.35 (2026-07-24), market cap ~$1.85B. The 52-week range ($18.57–$61.65) frames the picture: recovered ~160% off the low, still ~22% under the prior 12-month high.
• Price structure is a consolidation in the mid-to-high $40s, capped by the $52–54 analyst-target cluster and the $61 prior high. This is a base pressing against resistance, not a breakout above it.
• There is no accelerating momentum signature — declining WSEs and soft reported earnings argue MATURING at best. The parabolic recovery leg off the bottom has already been paid out.
• Beginner-trap flags to name plainly: the ~5% yield is a magnet for holding a weak name "for the dividend"; the print is ~2 trading days out, so a fresh entry here is a binary gamble; and buying a name whose core metric is still shrinking, into resistance, is chasing a recovery rather than catching a narrative.

Catalyst Calendar (next 30 days)

• Post-print quarterly dividend declaration typically follows earnings (~$0.60/share, est.).

Elapsed catalysts

• 2026-07-29 (Wed, after close): Q2 2026 earnings. Consensus ~$0.33 adjusted EPS on ~$1.67B revenue. This is the binary — WSE trajectory, gross-profit-per-employee, and any hard HRScale booking/client numbers will set the tape. Earnings inside three trading days = avoid fresh entries into the print. (passed 11d ago)

What Would Change Our Mind

• Bull activation: a worksite-employee inflection on 2026-07-29 — a full-year guide raised above 307,000 or a return toward YoY WSE growth — plus disclosed HRScale client counts. That would flip the turnaround toward accelerating and justify a fresh look on a clean breakout over the $52–54 shelf.
• Bear confirmation: a second WSE guide cut or a margin miss on the print, or the price losing its recovery base.

Correlation Notes

• NSP is cyclical to US small-business hiring — it tracks small-employer employment (NFIB hiring plans, ADP small-business payrolls) far more than the S&P tech complex.
• PEO/payroll peer read-across: TriNet (TNET), Barrett Business Services (BBSI), Paychex (PAYX), ADP (ADP). Health-insurer medical-cost-trend commentary is a leading tell for NSP's benefits-margin risk.
• The Workday (WDAY) relationship ties a slice of the equity story to Workday's SMB push; WDAY partnership commentary is a secondary read on HRScale traction.